Evidence map›Paper›PMID 26336885›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015

Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.

Esma Saâda-Bouzid, Fanny Burel-Vandenbos, Dominique Ranchère-Vince, Isabelle Birtwisle-Peyrottes, Bruno Chetaille, Corinne Bouvier, Marie-Christine Château, Michel Peoc'h, Maxime Battistella, Audrey Bazin and 5 more

Open access · bronzeAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 100 citations in OpenAlex.

  1. Article
  2. Solitary fibrous tumor: an updated review.Journal of pathology and translational medicine · 2026
    Article
  3. Prognostic Implications of MDM2 and CDK4 Co-amplification in Liposarcoma: Insights from FISH analysis for Translational Oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Oncogenic Functions of Alternatively SplicedInternational journal of molecular sciences · 2024
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024
    Article
  17. Review
  18. Review
  19. Cancers · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Esma Saâda-BouzidLaboratory of Solid Tumor Genetics, IRCAN, Nice University Hospital, Nice, France.
Fanny Burel-VandenbosCentral Laboratory of Pathology, Nice University Hospital, Nice, France.
Dominique Ranchère-VinceBiopathology Department, Centre Léon-Bérard, Lyon, France.
Isabelle Birtwisle-PeyrottesLaboratory of Cytology and Pathology, Centre Antoine-Lacassagne, Nice, France.
Bruno ChetailleBiopathology Department, Institut Paoli-Calmettes, Marseille, France.
Corinne BouvierPathology Department, Marseille University Hospital La Timone, Marseille, France.
Marie-Christine ChâteauLaboratory of Cytology and Pathology, Centre Val d'Aurelle, Montpellier, France.
Michel Peoc'hLaboratory of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France.
Maxime BattistellaLaboratory of Pathology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France.
Audrey BazinLaboratory of Solid Tumor Genetics, IRCAN, Nice University Hospital, Nice, France.
Jocelyn GalDepartment of Biostatistics, Centre Antoine-Lacassagne, Nice, France.
Jean-François MichielsCentral Laboratory of Pathology, Nice University Hospital, Nice, France.
Jean-Michel CoindreLaboratory of Pathology, Bergonie Institute, Bordeaux, France.
Florence PedeutourLaboratory of Solid Tumor Genetics, IRCAN, Nice University Hospital, Nice, France.
Laurence BianchiniLaboratory of Solid Tumor Genetics, IRCAN, Nice University Hospital, Nice, France.
Institut de Recherche sur le Cancer et le Vieillissement de Nice · FRCentre Antoine Lacassagne · FRCentre Hospitalier Universitaire de Nice · FRAssistance Publique – Hôpitaux de Paris · FRCEA Valduc · FRCentre Hospitalier Universitaire de Saint-Étienne · FRCentre Léon Bérard · FRInserm · FRInstitut Bergonié · FRInstitut Paoli-Calmettes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HMGA2, CDK4, and JUN genes have been described as frequently coamplified with MDM2 in atypical lipomatous tumor, well-differentiated liposarcoma, and dedifferentiated liposarcoma. We studied the frequency of amplification of these genes in a series of 48 dedifferentiated liposarcomas and 68 atypical lipomatous tumors/well-differentiated liposarcomas. We correlated their amplification status with clinicopathological features and outcomes. Histologically, both CDK4 (P=0.007) and JUN (P=0.005) amplifications were associated with dedifferentiated liposarcoma, whereas amplification of the proximal parts of HMGA2 (5'-untranslated region (UTR) and exons 1-3) was associated with atypical lipomatous tumor/well-differentiated liposarcoma (P=0.01). CDK4 amplification was associated with axial tumors. Amplification of 5'-UTR and exons 1-3 of HMGA2 was associated with primary status and grade 1. Shorter overall survival was correlated with: age >64 years (P=0.03), chemotherapy used in first intent (P<0.001), no surgery (P=0.003), grade 3 (P<0.001), distant metastasis (P<0.001), node involvement (P=0.006), and CDK4 amplification (P=0.07). In multivariate analysis, distant metastasis (HR=8.8) and grade 3 (HR=18.2) were associated with shorter overall survival. A shorter recurrence-free survival was associated with dedifferentiated liposarcoma (P<0.001), grade 3 (P<0.001), node involvement (P<0.001), distant metastasis (P=0.02), recurrent status (P=0.009), axial location (P=0.001), and with molecular features such as CDK4 (P=0.05) and JUN amplification (P=0.07). Amplification of 5'-UTR and exons 1-3 (P=0.08) and 3'-UTR (P=0.01) of HMGA2 were associated with longer recurrence-free survival. Distant metastasis was associated with shorter recurrence-free survival (HR=5.8) in multivariate analysis. Dedifferentiated liposarcoma type was associated with axial location, grade 3 and recurrent status. In conclusion, we showed that the amplification of HMGA2 was associated with the atypical lipomatous tumor/well-differentiated liposarcoma histological type and a good prognosis, whereas CDK4 and JUN amplifications were associated with dedifferentiated liposarcoma histology and a bad prognosis. In addition, we also provided the first description of the molecular evolution of a well-differentiated liposarcoma into four successive dedifferentiated liposarcoma relapses, which was consistent with our general observations.

Indexed as

Gene AmplificationAdultAgedBiomarkers, TumorComparative Genomic HybridizationCyclin-Dependent Kinase 4Disease-Free SurvivalFemaleGenes, junHMGA2 ProteinHumansImmunohistochemistryIn Situ Hybridization, FluorescenceKaplan-Meier EstimateLiposarcomaMaleBiomarkers, TumorCDK4 protein, humanCyclin-Dependent Kinase 4HMGA2 ProteinOncogene Protein p65(gag-jun)

Identifiers

PMID26336885
OpenAlexW1258808631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.